Lanxess (LXS) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
26 Dec, 2025Executive summary
2024 was a challenging year with weak macroeconomic demand, but profitability improved due to accelerated cost savings, higher utilization rates, and operational discipline.
The FORWARD! program delivered €110m in cost savings in 2024, with €40m more expected in 2025.
Portfolio transformation advanced, focusing on chemicals and divesting polymers, with all regulatory clearances received for the urethane transaction, expected to close in April 2025.
Free cash flow remained solid, and financial leverage decreased by roughly EUR 100 million, with further deleveraging planned using proceeds from the urethane sale.
Safety performance remained top-tier in the European industry for the third consecutive year.
Financial highlights
EBITDA increased by 20% year-over-year, reaching €614m in 2024, with margin at 9.6%.
FY 2024 sales declined 5% to €6,366m; Q4 2024 sales up 3% to €1,483m; EBITDA pre up 64% to €159m in Q4.
Net income for FY 2024 at -€177m, impacted by prior year goodwill impairment and lower book gains.
Free cash flow for FY 2024 at €188m, supported by improved operating result and disciplined capex.
Adjusted EPS for Q4 2024 at €0.21, up from -€0.30 in Q4 2023.
Outlook and guidance
2025 guidance for reported EBITDA is €600–650m, including pro rata Urethane Systems contribution, with only modest macroeconomic improvement expected.
Q1 2025 EBITDA is expected to improve by 25%-35% compared to Q1 2024.
All segments expected to contribute to EBITDA growth in 2025, though caution remains on agro demand.
Capex planned at €330m and operational depreciation at €370m for 2025.
Stable dividend of €0.10 proposed for 2024, maintaining focus on deleveraging.
Latest events from Lanxess
- Earnings rose, costs fell, and sustainability advanced amid global uncertainty and strategic refocus.LXS
AGM 20253 Feb 2026 - Q2 2024 EBITDA pre exceptionals surged 69% year-over-year despite lower sales.LXS
Q2 20241 Feb 2026 - EBITDA pre exceptionals jumped 45% and net income returned to profit in Q3 2024.LXS
Q3 202416 Jan 2026 - Q2 sales and EBITDA fell on weak demand, but net debt dropped after Urethane divestment.LXS
Q2 202523 Nov 2025 - EBITDA pre up 32% to €133m; guidance held as Urethane sale supports debt reduction.LXS
Q1 202517 Nov 2025 - EBITDA pre exceptionals rose 32% in Q1 2025, with guidance confirmed at €600–650 million.LXS
Q1 2025(Media)17 Nov 2025 - Sales and EBITDA fell sharply in Q3 2025, with cost cuts and divestments improving leverage.LXS
Q3 20256 Nov 2025 - Phased exit of JV stake begins, unlocking over €1.2bn in value with EBITDA-linked upside.LXS
Investor Update16 Oct 2025